Olaparib therapy combined with CHK1i selectively radiosensitizes p53 mutant pancreatic cancer cells, suggesting that inhibition of HR by CHK1i is a useful strategy for selective induction of a BRCA1 “deficient-like” phenotype in p53 mutant tumor cells sparing normal tissue [54]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.